Moderna (NASDAQ:MRNA) Posts Quarterly Earnings Results, Beats Estimates By $0.68 EPS

Moderna (NASDAQ:MRNA) released its earnings results on Friday. The company reported ($2.11) earnings per share for the quarter, beating the consensus estimate of ($2.79) by $0.68, FiscalAI reports. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company had revenue of $678.00 million for the quarter, compared to analysts’ expectations of $611.14 million. During the same quarter in the previous year, the business posted ($2.91) EPS. The business’s revenue for the quarter was down 33.2% on a year-over-year basis.

Here are the key takeaways from Moderna’s conference call:

• The FDA issued a refusal‑to‑file for Moderna’s seasonal flu candidate mRNA‑1010, delaying U.S. approval and forcing a Type A meeting to define next steps — this creates regulatory uncertainty that could postpone U.S. launches and affect related revenue timing.
• Moderna cut operating expenses by about $2.2 billion (≈30%) in 2025, finished the year with $8.1 billion in cash and investments, and expects to end 2026 with $5.5–$6.0 billion of cash while targeting $4.2 billion of cash costs, providing runway while advancing the pipeline.
• Commercial momentum is strong — mNEXSPIKE captured ~24% of the U.S. retail COVID market (34% in ages 65+), and management expects up to 10% revenue growth in 2026 driven by international launches, local manufacturing in the U.K./Australia, and multi‑year government agreements.
• Multiple pipeline catalysts are upcoming — INT (individualized cancer therapy) reported positive 5‑year phase‑2 melanoma data and has several fully enrolled late‑stage trials (melanoma, RCC, muscle‑invasive bladder), while norovirus and propionic acidemia registrational studies are fully enrolled with potential 2026 readouts.

Moderna Price Performance

Moderna stock traded up $2.45 during trading hours on Friday, hitting $42.56. The company had a trading volume of 10,831,075 shares, compared to its average volume of 13,325,186. The firm has a 50-day moving average of $36.97 and a 200 day moving average of $29.81. The firm has a market cap of $16.63 billion, a PE ratio of -5.28 and a beta of 1.32. Moderna has a one year low of $22.28 and a one year high of $55.20.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Q4 beat on revenue and a narrower loss — Moderna reported GAAP EPS of ($2.11) and revenue of $678M, both better than Street expectations, which investors view as a meaningful operating improvement vs. prior quarters. Read More.
• Positive Sentiment: Management reaffirmed a target of ~10% revenue growth and reiterated FY guidance (roughly $2.1B revenue), highlighting cost reductions and continued commercial traction—signals that support a recovery narrative for future cash flows. Read More.
• Neutral Sentiment: Pipeline and enrollment progress: Moderna flagged full enrollment in several trials (e.g., norovirus Phase 3) and other R&D advances; these are medium‑term value drivers but not immediate revenue contributors. Read More.
• Negative Sentiment: Regulatory setback on flu vaccine — the FDA issued a Refusal‑to‑File for mRNA‑1010 citing trial comparator/design issues; that delays a key potential U.S. seasonal vaccine revenue stream and raises near‑term regulatory risk. The company says it has requested a Type A meeting to clarify next steps. Read More.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MRNA shares. TD Cowen reiterated a “hold” rating on shares of Moderna in a report on Thursday, January 29th. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a research report on Monday, December 1st. UBS Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and decreased their target price for the company from $40.00 to $34.00 in a research report on Tuesday, January 6th. Morgan Stanley reduced their target price on shares of Moderna from $30.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Finally, Citigroup restated a “neutral” rating on shares of Moderna in a research report on Monday, January 19th. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, Moderna currently has an average rating of “Reduce” and a consensus price target of $28.77.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of Moderna stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This trade represents a 85.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 10.90% of the company’s stock.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently modified their holdings of MRNA. Kintegral Advisory LLC acquired a new stake in Moderna during the fourth quarter worth about $85,000. Intesa Sanpaolo Wealth Management bought a new stake in shares of Moderna during the 4th quarter worth approximately $153,000. Brown Brothers Harriman & Co. boosted its position in shares of Moderna by 35.4% during the 4th quarter. Brown Brothers Harriman & Co. now owns 2,671 shares of the company’s stock worth $79,000 after acquiring an additional 699 shares in the last quarter. Zions Bancorporation National Association UT increased its stake in Moderna by 2,805.3% in the fourth quarter. Zions Bancorporation National Association UT now owns 4,968 shares of the company’s stock valued at $147,000 after acquiring an additional 4,797 shares during the last quarter. Finally, State of Wyoming raised its position in Moderna by 43.6% during the fourth quarter. State of Wyoming now owns 3,032 shares of the company’s stock valued at $89,000 after purchasing an additional 920 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.